Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape
Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
[HTML][HTML] The glymphatic system: Current understanding and modeling
We review theoretical and numerical models of the glymphatic system, which circulates
cerebrospinal fluid and interstitial fluid around the brain, facilitating solute transport. Models …
cerebrospinal fluid and interstitial fluid around the brain, facilitating solute transport. Models …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease
NR Barthélemy, K Horie, C Sato… - Journal of Experimental …, 2020 - rupress.org
Highly sensitive and specific plasma biomarkers for Alzheimer's disease (AD) have the
potential to improve diagnostic accuracy in the clinic and facilitate research studies including …
potential to improve diagnostic accuracy in the clinic and facilitate research studies including …
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …
understanding of the timing of disease-related changes in tau. We quantified the …
High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018 - nature.com
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease,, supportive …
expected to be most efficacious at the earliest and mildest stages of the disease,, supportive …
The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans
The sleep-wake cycle regulates interstitial fluid (ISF) and cerebrospinal fluid (CSF) levels of
β-amyloid (Aβ) that accumulates in Alzheimer's disease (AD). Furthermore, chronic sleep …
β-amyloid (Aβ) that accumulates in Alzheimer's disease (AD). Furthermore, chronic sleep …
[HTML][HTML] NIA-AA research framework: toward a biological definition of Alzheimer's disease
CR Jack Jr, DA Bennett, K Blennow, MC Carrillo… - Alzheimer's & …, 2018 - Elsevier
Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …
[HTML][HTML] Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice
Background Slowed clearance of amyloid β (Aβ) is believed to underlie the development of
Aβ plaques that characterize Alzheimer's disease (AD). Aβ is cleared in part by the …
Aβ plaques that characterize Alzheimer's disease (AD). Aβ is cleared in part by the …
Amyloid-type protein aggregation and prion-like properties of amyloids
This review will focus on the process of amyloid-type protein aggregation. Amyloid fibrils are
an important hallmark of protein misfolding diseases and therefore have been investigated …
an important hallmark of protein misfolding diseases and therefore have been investigated …